The FDA says J&J's (JNJ -0.3%) bedaquiline for treating a drug-resistant form of...
The FDA says J&J's (JNJ -0.3%) bedaquiline for treating a drug-resistant form of tuberculosis appears to be "safe and well-tolerated," although the highest dose could cause a small change in the heart's rhythm. J&J is seeking accelerated, temporary approval of bedaquiline; an FDA advisory committee is due to review the drug on Wednesday.
From other sites
Video at CNBC.com (Jul 20, 2015)
Video at CNBC.com (Jul 14, 2015)
Video at CNBC.com (May 27, 2015)
at CNBC.com (May 22, 2015)
Video at CNBC.com (May 20, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs